Navigation Links
Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients

onal pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R) and Neurontin(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the dat
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
2. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
3. Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective
4. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
5. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
6. Point of Care Strep Tests Speed Treatment, Lower Costs
7. Rapid HIV Testing Increases Possibility of Treatment
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
(Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... 13, 2011 BD (Becton, Dickinson and Company) (NYSE: ... a subsidiary of Waste Management, Inc. (NYSE: ... sharps waste from hospitals and other healthcare facilities.  The ... Solution, an innovative service that will recycle medical sharps ...
... Healthcare Financial Management Association (HFMA) has recognized the ... ("SIS") as once again consistently meeting the "Peer ... offerings as part of the annual evaluation process ... HFMA Peer Reviewed designation.  ...
Cached Medicine Technology:BD and Waste Management Launch Initiative to Recycle Medical Sharps 2BD and Waste Management Launch Initiative to Recycle Medical Sharps 3BD and Waste Management Launch Initiative to Recycle Medical Sharps 4Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 2Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 3
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Problems With Governor,s Mandatory Health Insurance Plan, ... today by the Schwarzenegger Administration fail to,protect patients ... decide which policies to cancel without prior review ... Consumer Rights (FTCR).,FTCR said that the weak cancellation ...
... Inc., an investment,company with a series of 20 ... by Standard & Poor,s, the calculating agent for ... trading on,Friday, October 26, 2007, Immunogen, Inc. (Nasdaq: ... BIVN ) in the HealthShares(TM) Emerging Cancer,Index. Bioenvision, ...
... Offers Tips for People with Diabetes Affected ... by California Wildfires, ... the following tips for people with diabetes who,are affected by the ... with diabetes,require additional supplies to manage their health. 1) Medication ...
... on November 13, 2007 at 8:00 am ... 9:00 pm (Beijing/Hong Kong), SHANGHAI, China, Oct. 23 ... ("WuXi PharmaTech" or "the Company"), the leading,China-based pharmaceutical and ... will release unaudited,financial results for the third quarter ended ...
... PDT (8:00 p.m. EDT), SUNNYVALE, Calif., Oct. 23 ... field of radiosurgery,announced today that it will host an investor ... the American Society of,Therapeutic Radiology and Oncology (ASTRO) in Los ... PDT. A live webcast of the presentation will begin ...
... -- Mayo Clinic today reported promising interim results from ... for patients with recurrent ovarian cancer that is resistant ... either complete or partial tumor regression from the therapy, ... this Phase 2 Consortium (P2C) clinical trial were presented ...
Cached Medicine News:Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 2Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 3Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 3Health News:Emergency Preparedness for People With Diabetes 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 3Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 2Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 3Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2
... For the quantitative determination of ... ,Patients with atopic allergic diseases such ... fever have been shown to exhibit ... blood. IgE is also known as ...
...
...
...
Medicine Products: